Challenges in Interpretation of Staging PET/CT in Thoracic Malignancies

Girish S. Shroff*, Brett W. Carter, Chitra Viswanathan, Marcelo F. Benveniste, Carol C. Wu, Edith M. Marom, Osama R. Mawlawi, Mylene T. Truong

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


18F-fluorodeoxryglucose (18F-FDG) PET/CT imaging is routinely performed in the evaluation of patients with known or suspected thoracic malignancy. Indications for its use include staging of malignancy, assessment of response to therapy, evaluation of suspected disease recurrence, and evaluation of a solitary pulmonary nodule. In this article, we will discuss specific technical artifacts and also review potential pitfalls in the interpretation of PET/CT in thoracic malignancies including normal variations in physiologic uptake of FDG, benign conditions (such as infection, inflammation, posttreatment changes, and iatrogenic factors) that can result in increased FDG uptake, and malignancies that demonstrate scarce to no FDG uptake.

Original languageEnglish
Pages (from-to)330-341
Number of pages12
JournalCurrent Problems in Diagnostic Radiology
Issue number4
StatePublished - Jul 2017
Externally publishedYes


Dive into the research topics of 'Challenges in Interpretation of Staging PET/CT in Thoracic Malignancies'. Together they form a unique fingerprint.

Cite this